<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04403139</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00009255</org_study_id>
    <secondary_id>R01AG064800</secondary_id>
    <nct_id>NCT04403139</nct_id>
  </id_info>
  <brief_title>VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination</brief_title>
  <official_title>VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating
      T-cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional study of vaccination related to infection with varicella zoster
      virus. We will enroll participants of two age groups. Cohort 1 will be persons between the
      ages of 30-40; Cohort 2 will be persons who are 70 years of age or older. All participants
      will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the
      approved dose and schedule.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of gE-specific IgG in serum.</measure>
    <time_frame>up to 1 year after vaccination</time_frame>
    <description>Units will be optical density at 492 nanometers from ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of gE-specific CD4 T cells in blood</measure>
    <time_frame>up to 1 year after vaccination</time_frame>
    <description>Units will be cells per million CD4+ T cells in blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine profile of gE-specific CD4 T cells in blood</measure>
    <time_frame>up to 1 year after vaccination</time_frame>
    <description>Units will be percent of gE-reactive T cells expressing single T cell cytokines or combinations of cytokines</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Varicella Zoster Virus Infection</condition>
  <arm_group>
    <arm_group_label>Cohort 1: 30-40 year of age</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 70 years of age or older</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Shingrix</intervention_name>
    <description>All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.</description>
    <arm_group_label>Cohort 1: 30-40 year of age</arm_group_label>
    <arm_group_label>Cohort 2: 70 years of age or older</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cohort 1: 30-40 years of age

          -  Cohort 2: 70 years of age or older

          -  HIV seronegative

        Exclusion Criteria:

          -  Previous vaccination with Shingrix (RZV), Zostavax (ZVL, zoster vaccine live), or with
             the chickenpox vaccine

          -  VZV seronegative

          -  Active Hepatitis C infection or active Hepatitis B infection. Persons with serologic
             evidence of hepatitis C infection that has cleared spontaneously, or with a history of
             treated hepatitis C with a sustained virologic response, can be enrolled. Persons with
             a history of resolved hepatitis B infection (negative for hepatitis B surface antigen)
             can be enrolled

          -  History of a life-threatening allergic reaction (anaphylactic/anaphylactoid reaction)
             to any component of the vaccine

          -  History of receipt of an organ transplant or hematopoietic stem cell transplant

          -  Significant autoimmune disease such as rheumatoid arthritis, psoriatic arthritis,
             inflammatory bowel disease, multiple sclerosis, scleroderma, dermatomyositis, or other
             condition which in the past has required significant immune modifying medication or
             which has a clinical course that is characterized by relapses

          -  Has immunosuppression as a result of an underlying illness (e.g. leukemia, lymphoma or
             other malignant neoplasms) or treatment with immunosuppressive or cytotoxic drugs, or
             use of anticancer chemotherapy or radiation therapy.

          -  Has long-term use of oral or parenteral steroids (&gt;7 days), or high-dose inhaled
             steroids (&gt;800 mcg/day of beclomethasone dipropionate or equivalent) within the
             preceding 6 months (nasal and topical steroids are allowed)

          -  Women of child-bearing potential only: pregnant, breastfeeding, or planning to become
             pregnant 3 months post vaccination

          -  Has an acute or chronic medical condition that, in the opinion of the investigator,
             would render biopsies unsafe

          -  History of coagulopathy or taking medication that may cause bleeding (long term high
             dose aspirin, heparin, coumadin). Aspirin doses &lt;100 mg daily allowed

          -  History of keloid formation or excessive scarring

          -  History of frequent cellulitis or boils (&gt;3 episodes in past 2 years) requiring
             antibiotic therapy

          -  Allergy to lidocaine, silver nitrate, or mupirocin

          -  Has any condition or medical history that would, in the opinion of the site principal
             investigator place the subject at an unacceptable risk of injury or render the subject
             unable to meet the requirements of the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine M Johnston, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virology Research Clinic</last_name>
    <phone>206-520-4340</phone>
    <email>vrc@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Washington Virology Research Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Christine Johnston</investigator_full_name>
    <investigator_title>Associate Professor: School of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Varicella Zoster Virus Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

